SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Key Highlights
- ➤Arbli™ added to formularies at three leading U.S. pediatric academic medical centers
- ➤U.S. losartan market approximately $219 million in sales and 72 million prescriptions annually
- ➤Wholesale orders for Arbli™ continue increasing sequentially
- ➤Arbli™ provides ready-to-use 10 mg/mL oral suspension without pharmacy compounding
Expert Statements
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture
“The commercial rollout of Arbli(™) has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels.”
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture
“These formulary additions represent an important growth milestone in the commercialization of Arbli(™) and, importantly, its adoption within the pediatric healthcare setting, where the product provides much needed patient benefits.”
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture
“With the U.S. losartan market representing approximately $219 million in sales annually, even modest market penetration could represent a meaningful commercial opportunity for Arbli(™).”
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture
“The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as we continue to expand Arbli(™)’s market penetration.”
Narasimhan Mani, President and Co-Chief Executive Officer of Scienture
“We believe the combination of expanding institutional adoption, increasing wholesale orders and a highly attractive market opportunity provides a strong foundation for continued growth.”
Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture
“We believe this is just the beginning of the opportunity for Arbli(™) within the pediatric hospital market.”
Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture
“We believe the addition of Arbli(™) by leading pediatric academic medical centers can help support our efforts to expand adoption across other institutions.”
Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture
“We remain focused on building broader hospital and institutional access while continuing to expand payer coverage, pharmacy availability and distribution nationwide.”
Major Institutional Formulary Win Expands Arbli(™)’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
Arbli(™) Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually
Get started
Create a free account to read the full story.